Breaking News on Contract Research, Manufacturing & Clinical Trials

Latest news headlines

Products

Suppliers

Wockhardt to build manufacturing hub in India

04-Oct-2006 - Indian biopharmaceutical company Wockhardt has signed a deal with Maharashtra Industrial Development Corporation (MIDC) to establish a special economic zone (SEZ) in Aurangabad, India, in order to expand its manufacturing capabilities.

Discovery Labs looks to FDA to end manufacturing ordeal

04-Oct-2006 - Following numerous manufacturing failures, Discovery Laboratories believes it has resolved the stability issues that have plagued Surfaxin, its experimental respiratory treatment for infants, and is now seeking a meeting with the US Food and Drug Administration (FDA) to address its concerns.

Aptuit spreads its wings with EaglePicher API deal

02-Oct-2006 - Drug developing services provider Aptuit has acquired the pharmaceutical services division of technology firm EaglePicher, enriching its active pharmaceutical ingredient (API) and drug substance manufacturing offerings.

Ferro enters drug delivery in supercritical fashion

26-Sep-2006 - Ferro Pfanstiehl Laboratories has commissioned a new validated current good manufacturing practice (cGMP) supercritical fluid-based particle engineering pilot facility, offering sizing, purification and formulation services to its pharmaceutical customers.

Patheon's future up in the air as profits plummet

25-Sep-2006 - Patheon's move to Puerto Rico is shaping up to be the worst decision the contract manufacturer has ever made, resulting in massive losses in the third quarter of 2006 and leading management to entertain the possibility of a sell-out.

Bentley Pharma to use Cardinal's facility for nasal insulin manufacture

22-Sep-2006 - Bentley Pharmaceuticals has announced it will use the North Carolina facilities of US-based services provider Cardinal Health for the scale-up and manufacture of the clinical supplies of its new intranasal insulin product.

Cardinal gets green light for new sterile facility start-up

19-Sep-2006 - Cardinal Health has been given the green light from the US Food and Drug Administration (FDA) to start manufacturing the first commercial drug at its new sterile facility in North Carolina.

Kemwell seals Pfizer plant deal

18-Sep-2006 - Kemwell has sealed the deal on the purchase of Pfizer's Swedish manufacturing plant and at the same time secured a long-term contract manufacturing agreement with the drug giant.

How to avoid contract manufacturing disappointment

14-Sep-2006 - Successful technology transfer and effective management can help avoid disappointment with contract manufacturing arrangements, which often fail to live up to pharmaceutical company expectations.

Intercell's adjuvant stimulates Wyeth

14-Sep-2006 - Wyeth has entered into a global agreement that allows it to use Intracell's synthetic adjuvant IC31 in the formulation of five of its investigational vaccines, aiming to simply mix it with antigens without the need for conjugation.

Choosing the right contract manufacturer

13-Sep-2006 - A good selection process, with a realistic set of selection criteria is essential when looking for the right contract manufacturing partner, according to a new Datamonitor report.

Offshore manufacturing - not always the best option

12-Sep-2006 - Offshoring contract manufacturing is not the only option for large pharma firms looking to drive productivity and efficiency gains in drug manufacturing, warns a new report from independent market analyst Datamonitor.

Cardinal facility buyback brings Mucinex production in-house

05-Sep-2006 - After selling a manufacturing plant in Texas to Cardinal Health two years ago, Adams Respiratory Therapeutics has reacquired the facility in order to produce its expectorant Mucinex (guaifenesin extended-release), responding to a 15-fold growth in sales in the last couple of years.

Patheon breaks into drug delivery

29-Aug-2006 - Canadian contract manufacturer Patheon has teamed up with specialty pharmaceutical firm Depomed to offer its clients a controlled release formulation which can grant their drugs increased bioavailability and less frequent dosing.

Consumables and contract manufacturing the drivers of the bioprocessing industry

23-Aug-2006 - Despite its consolidation, the competitive consumable sector still offers potential for rapid growth and better profits in the biopharmaceutical industry, while contract bioprocessing services will be increasingly in demand, according to a new market report by D&MD Publications titled "The Bioprocessing Industry - Increasing Capacity, Production, and Efficiency."

Merck offers first glimpse of $300m vaccine plant

23-Aug-2006 - For the first time Merck has opened the doors of its under-construction manufacturing plant in North Carolina to public officials, boasting it will eventually contribute about two-thirds of its annual live-virus vaccine production.

Pearlescent pigments may help halt counterfeiting, says Merck

17-Aug-2006 - Newly-approved pearlescent pigments that can produce sparkly metallic, satiny and shimmery finishes on drug coatings could be used as one additional step in the fight against counterfeiting, say its developers, EMD Chemicals - part of part of German drug giant Merck.

India geared up for unprecedented manufacturing growth

15-Aug-2006 - India's potential to further boost its already dominant role in global generics production, as well as an offshore location of choice for contract manufacturing, presents an opportunity worth an estimated $48bn (€38bn) in 2007, though regulatory reforms and improved intellectual property rights are needed if its domestic market is to be tapped, a new report from KPMG suggests.

Manufacturing double whammy to cost Patheon millions

15-Aug-2006 - More problems at Patheon's Puerto Rican production facilities in the third quarter of 2006 are expected to reduce the contract manufacturer's earnings before interest, tax, depreciation and amortisation (EBITDA) by more than $9m (€7m) compared to last year, forcing it to negotiate its credit agreement with its lenders.

West profits surge; Exubera contract gains momentum

08-Aug-2006 - West Pharmaceutical Services has reported a huge surge in both sales and profits for its second quarter, spurred on by the increasing demand for injectable drugs as well as the lucrative Exubera manufacturing contract, which helped double sales for the segment, although failed to stop a fall in profit margin.

When fine chemical firms flirt with drug delivery

08-Aug-2006 - Pharmaceutical excipients can have a profound impact on the release profile of drugs, driving fine chemical companies to raise their game since they realise their clients see excipients as more than inactive ingredients.

The whole nine yards in drug delivery development

03-Aug-2006 - More and more drugmakers are turning to health care companies not just for their drug delivery technologies but also for their regulatory and manufacturing expertise, asking them to take their product from early stages all the way to post-approval.

Japan and India eye each other for new pharma deals

20-Jul-2006 - The Japanese pharmaceutical industry is eyeing India as a new hub to conduct its contract manufacturing and clinical trials - India is thirsty for new Japanese investment.

Cardinal Health bags insulin spray manufacturing deal

29-Jun-2006 - After launching its flagship oral insulin spray in Ecuador last December, Generex is finally gearing up to take on big pharma in the global non-injectable insulin arena and has picked Cardinal Health to help meet manufacturing demands.

Cardinal gives best bang for the buck

18-May-2006 - Cardinal Health has taken the contract manufacturing crown after being honoured with a prestigious award from Frost & Sullivan in recognition of its ability to provide biopharma firms with a high quality service, while still remaining extremely competitively priced.